Page 31 - Expanded Access Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expanded access program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expanded Access Program Today - Breaking & Trending Today

Clarity's theranostic prostate cancer trial advances to cohort 2

Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy. ....

United States , New South Wales , Luke Nordquist , Alan Taylor , Urology Cancer Center Xcancer Omaha , Access Program , Clarity Pharmaceuticals , Prnewswire Clarity Pharmaceuticals , American Cancer Society , American Cancer Institute , Safety Review Committee , Drug Administration , Expanded Access Program , Prostate Specific Antigen , Prostate Specific Membrane Antigen , Targeted Copper Theranostics , Urologic Medical Oncologist , Principal Investigator , Urology Cancer Center , Executive Chairperson , Cancer Statistics , Mortality Worldwide , Cancer Society , Key Statistics , Prostate Cancer ,

Clarity's theranostic prostate cancer trial advances to cohort 2

Highlights Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. No dose limiting toxicities (DLTs) have been reported in cohort 1. The Safety Review Committee (SRC) has recommended that the trial continues to cohort 2. Recruitment has opened at clinical sites in the United States (US) at the cohort 2 dose level of 8GBq and patients are currently in screening for all available slots. Additional therapy cycles of 67Cu SAR-bisPSMA have been requested by clinicians under the US Food and Drug Administration (FDA) Expanded Access Program (EAP). Early data from the EAP indicates positive effects of the lowest dose of 67Cu SAR-bisPSMA on lesions, demonstrated by SPECT-CT images, with reduction in Prostate Specific Antigen (PSA) levels. SYDNEY, May 24, 2023 /PRNewswire/ Clarity Pharmaceuticals(ASX: CU6) ("Clarity", "the Company&quo ....

United States , New South Wales , Alan Taylor , Luke Nordquist , American Cancer Society , Prnewswire Clarity Pharmaceuticals , Urology Cancer Center Xcancer Omaha , Drug Administration , Access Program , Clarity Pharmaceuticals , Safety Review Committee , American Cancer Institute , Expanded Access Program , Prostate Specific Antigen , Prostate Specific Membrane Antigen , Targeted Copper Theranostics , Urologic Medical Oncologist , Principal Investigator , Urology Cancer Center , Executive Chairperson , Cancer Statistics , Mortality Worldwide , Cancer Society , Key Statistics , Prostate Cancer ,

Clarity's theranostic prostate cancer trial advances to cohort 2

Highlights SYDNEY, May 24, 2023 /PRNewswire/ Clarity Pharmaceuticals (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce the completion of cohort 1 and advancement to cohort 2 in the therapeutic phase of its Phase I/II. ....

New South Wales , United States , Alan Taylor , Luke Nordquist , Safety Review Committee , Urology Cancer Center Xcancer Omaha , Drug Administration , Prnewswire Clarity Pharmaceuticals , Access Program , American Cancer Institute , Clarity Pharmaceuticals , American Cancer Society , Expanded Access Program , Prostate Specific Antigen , Prostate Specific Membrane Antigen , Targeted Copper Theranostics , Urologic Medical Oncologist , Principal Investigator , Urology Cancer Center , Executive Chairperson , Cancer Statistics , Mortality Worldwide , Cancer Society , Key Statistics , Prostate Cancer ,

RedHill Provides R&D Update | MarketScreener

RedHill has elected to terminate RHB-204 s U.S. Phase 3 study for Non-tuberculosis Mycobacteria disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107. | May 22, 2023 ....

United Kingdom , Adi Frish , Redhill Biopharma , Corporate Business Development , Nuclear Countermeasures Program , Company Expanded Access Program , Company Annual Report On Form , Clinical Research Organizations , Redhill Biopharma Ltd , Exchange Commission , Prnewswire Redhill Biopharma Ltd , Non Tuberculosis Mycobacteria , Acute Radiation Syndrome , Hill Biopharma , Qualified Infectious Disease Product , Gilead Raday , Chief Operating Officer , Orphan Drug Designation , Generating Antibiotic Incentives Now Act , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report , Redhill Biopharma Ltd Stock Exchange , Press Release , Dvance Rdhl Us7574682024 ,

RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency

/PRNewswire/ RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has received. ....

United Kingdom , Redhill Biopharma , Adi Frish , Nasdaq Stock Market , Redhill Biopharma Ltd , Company Expanded Access Program , Exchange Commission , Corporate Business Development , Company Annual Report On Form , Market Value , Publicly Held Shares , Nasdaq Rules , Listing Rule , Nasdaq Listing Rule , Nasdaq Capital , Hill Biopharma , Private Securities Litigation Reform Act , Expanded Access Program , Annual Report ,